Willis Investment Counsel Boosts Stock Holdings in Labcorp Holdings Inc. $LH

Key Points

• Willis Investment Counsel boosted its stake in Labcorp by 6.2%, adding 3,818 shares to hold 64,996 shares worth about $16.31 million (≈0.08% of the company) as of the latest SEC filing.
• Labcorp beat quarterly EPS estimates ($4.07 vs. $3.95) while revenue slightly missed ($3.52B vs. $3.56B) and set FY2026 guidance of $17.55–$18.25 EPS
• Insiders have been selling recently (EVP sold 1,500 shares; CEO sold 8,705 shares), while institutional ownership remains high at 95.94% and insider ownership is about 0.84%.

Willis Investment Counsel grew its position in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) by 6.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,996 shares of the medical research company's stock after purchasing an additional 3,818 shares during the quarter. Willis Investment Counsel owned approximately 0.08% of Labcorp worth $16,306,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. HBK Sorce Advisory LLC lifted its holdings in Labcorp by 4.3% in the third quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company's stock valued at $254,000 after acquiring an additional 38 shares during the period. Pure Financial Advisors LLC increased its position in shares of Labcorp by 3.9% in the third quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company's stock valued at $292,000 after buying an additional 38 shares in the last quarter. Hantz Financial Services Inc. increased its position in shares of Labcorp by 48.8% in the third quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company's stock valued at $35,000 after buying an additional 40 shares in the last quarter. Burney Co. increased its position in shares of Labcorp by 0.5% in the third quarter. Burney Co. now owns 8,819 shares of the medical research company's stock valued at $2,532,000 after buying an additional 42 shares in the last quarter. Finally, Advisor OS LLC increased its position in shares of Labcorp by 5.4% in the third quarter. Advisor OS LLC now owns 821 shares of the medical research company's stock valued at $236,000 after buying an additional 42 shares in the last quarter. 95.94% of the stock is owned by hedge funds and other institutional investors.

Labcorp Trading Up 2.2%

Labcorp stock opened at $275.10 on Thursday. The stock has a market cap of $22.67 billion, a PE ratio of 26.30, a P/E/G ratio of 1.87 and a beta of 1.02. The stock has a 50-day moving average price of $274.52 and a 200 day moving average price of $268.89. Labcorp Holdings Inc. has a 52 week low of $209.38 and a 52 week high of $293.72. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60.

Labcorp (NYSE:LH - Get Free Report) last posted its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, topping analysts' consensus estimates of $3.95 by $0.12. The firm had revenue of $3.52 billion during the quarter, compared to analysts' expectations of $3.56 billion. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The firm's quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the business posted $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Equities research analysts predict that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Friday, February 27th were given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Friday, February 27th. Labcorp's dividend payout ratio (DPR) is currently 27.53%.

Analyst Upgrades and Downgrades

LH has been the subject of a number of research analyst reports. Wall Street Zen cut Labcorp from a "buy" rating to a "hold" rating in a research report on Saturday, April 4th. Morgan Stanley restated an "overweight" rating on shares of Labcorp in a research report on Tuesday, February 17th. Robert W. Baird raised their price target on Labcorp from $313.00 to $326.00 and gave the company an "outperform" rating in a research report on Wednesday, February 18th. Weiss Ratings upgraded Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, February 10th. Finally, JPMorgan Chase & Co. raised their price target on Labcorp from $319.00 to $330.00 and gave the company an "overweight" rating in a research report on Wednesday, February 18th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $307.70.

Insider Buying and Selling

In related news, EVP Brian J. Caveney sold 1,500 shares of Labcorp stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total transaction of $429,465.00. Following the completion of the sale, the executive vice president owned 30,107 shares in the company, valued at approximately $8,619,935.17. This trade represents a 4.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Adam H. Schechter sold 8,705 shares of Labcorp stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total value of $2,437,051.80. Following the sale, the chief executive officer owned 80,773 shares of the company's stock, valued at approximately $22,613,209.08. This represents a 9.73% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 16,113 shares of company stock worth $4,547,450. 0.84% of the stock is owned by company insiders.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.